Friday, 15 May 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 15 May 2026
News

One-and-done diabetes fix looms

 Posted 15 May 2026 AM

A 'one-and-done' gene therapy that could replace GLP-1 pills and injections has been approved for a phase 1/2 trial in Europe, and the biotech company behind it hopes to include Australia in the trial, too.

Fractyl Health, based near Boston in the US, has received clearance from European regulators to test its RJVA-001 gene therapy for type 2 diabetes in the Netherlands.

To see the whole article, please login

Popular

What cardiologists think of Reps
'Ignored': Pharma fury at Budget fail
Pharma crowned 'Most Impactful'
Where's the action? Patients ask
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home